Streetbeat News

Products Services

AILE

ANL

CDE

IAUX

INFA

LI

MNDR

TSLA

Tesla, Inc. (TSLA) shares fell 3.6% in pre-market trading after announcing a $2,000 price cut for its U.S. electric-vehicle lineups, affecting its shares and those of other companies. iLearningEngines, Inc. (AILE), Adlai Nortye Ltd. (ANL), Li Auto Inc. (LI), Mobile-health Network Solutions (MNDR), Coeur Mining, Inc. (CDE), i-80 Gold Corp. (IAUX), and Informatica Inc. (INFA) also saw declines in pre-market trading due to various factors including market reactions to Tesla's price cut, pullbacks in precious metals prices, and acquisition talks.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:04 pm

CPNG

TAST

Two consumer discretionary stocks, Carrols Restaurant Group, Inc (TAST) and Coupang, Inc. (CPNG), are highlighted as overbought with RSI values above 70, signaling potential short-term performance concerns. TAST's stock rose after a 13D filing showed a 3.27% stake by Gabelli Funds, while CPNG plans to raise its membership fees by 58%, affecting its stock negatively.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:03 pm

ELAB

Elevai Labs, Inc. (ELAB) has entered into a distribution agreement with ILIA International Ltd. for the distribution of its products in Taiwan. This strategic move aims to expand ELAB's market presence in Asia.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:03 pm

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 12:00 pm

ADIL

Adial Therapeutics has expanded its intellectual property protection with a new patent covering the combination of its proprietary genetic diagnostic to identify patients with specific genotypes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:00 pm

JNJ

The European Commission (EC) has approved Carvykti for the treatment of relapsed or refractory multiple myeloma, according to Bloomberg. This approval marks a significant milestone for patients with this condition, offering a new therapeutic option. Johnson & Johnson (JNJ), likely involved in the development or distribution of Carvykti, may see a positive impact from this news.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:57 am

DGX

Quest Diagnostics has expanded its suite of services with the addition of p-tau217 blood biomarker testing, aimed at assessing risk and aiding in the diagnosis of Alzheimer's Disease. This development represents an advancement in the early detection and management of Alzheimer's, leveraging blood-based biomarkers for a more accessible and potentially earlier diagnosis.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:56 am

CTSH

MSFT

Cognizant (NASDAQ:CTSH) and Microsoft Corp. (NASDAQ:MSFT) have expanded their partnership to drive the adoption of Microsoft's generative AI and Copilots across enterprises, aiming to transform business operations and accelerate innovation. This collaboration is expected to significantly contribute to the U.S. and India's GDP through AI adoption. Cognizant has also invested in 25,000 Microsoft 365 Copilot seats and plans to deploy these technologies to a million users within their global clients across various industries.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:52 am

LI

Li Auto shares are trading lower following reports of the company implementing price cuts on its vehicles.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:49 am

MLEC

Moolec Science shares surged following the announcement of USDA approval for its plant-grown animal proteins, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:42 am